Most Popular
-
1
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
2
Jung's paternity reveal exposes where Korea stands on extramarital babies
-
3
Samsung entangled in legal risks amid calls for drastic reform
-
4
Opposition chief acquitted of instigating perjury
-
5
[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
-
6
Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
-
7
Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
-
8
[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance
![[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050072_0.jpg&u=)
-
9
[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle
![[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050043_0.jpg&u=20241126145342)
-
10
Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push
![[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050072_0.jpg&u=)
![[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050043_0.jpg&u=20241126145342)
SK Bioscience's COVID-19 vaccine candidate inches closer to launch after experts' approval recommendation
By YonhapPublished : June 27, 2022 - 10:43
South Korea's first COVID-19 vaccine candidate, developed by SK Bioscience Co., has received an approval recommendation from a government advisory group of pharmaceutical experts, officials said Monday, pushing the vaccine candidate one step closer to commercial launch.
The Ministry of Food and Drug Safety said GBP510, the vaccine candidate developed by SK Bioscience, was recommended during a meeting of the ministry's Central Pharmaceutical Review Committee on Sunday as being ready for "item approval" in terms of its safety and efficacy.
GBP510, also known as SKYCovione, is the country's first homegrown vaccine candidate to have successfully completed all three phases of its clinical trial.
The vaccine candidate is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize the immune effect. It was jointly developed with the University of Washington Antigen Design Research Institute.
The government has reached a deal to buy 10 million doses of SK Bioscience's vaccine. (Yonhap)
